IDORSIA AG
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commer… Read more
IDORSIA AG (19T) - Total Liabilities
Latest total liabilities as of June 2025: €1.64 Billion EUR
Based on the latest financial reports, IDORSIA AG (19T) has total liabilities worth €1.64 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IDORSIA AG - Total Liabilities Trend (2021–2024)
This chart illustrates how IDORSIA AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IDORSIA AG Competitors by Total Liabilities
The table below lists competitors of IDORSIA AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
China | CN¥3.93 Billion |
|
Hunan Aerospace Huanyu Communication Technology Co. Ltd. A
SHG:688523
|
China | CN¥725.20 Million |
|
Salzgitter AG
PINK:SZGPF
|
USA | $6.16 Billion |
|
MultiChoice Group Ltd
PINK:MCOIF
|
USA | $37.64 Billion |
|
Ethan Allen Interiors Inc
NYSE:ETD
|
USA | $236.68 Million |
|
Quanta Storage
TWO:6188
|
Taiwan | NT$5.08 Billion |
|
Xiamen Jihong Package Technology Ltd
SHE:002803
|
China | CN¥1.42 Billion |
|
Gas Malaysia Bhd
KLSE:5209
|
Malaysia | RM2.13 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down IDORSIA AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IDORSIA AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IDORSIA AG (2021–2024)
The table below shows the annual total liabilities of IDORSIA AG from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.72 Billion | +16.98% |
| 2023-12-31 | €1.47 Billion | -6.16% |
| 2022-12-31 | €1.57 Billion | +13.52% |
| 2021-12-31 | €1.38 Billion | -- |